Patient: Page 26
-
PharmaVoice Team/PharmaVoice
Planting the Seeds of a Blockbuster
Until fairly recently, top tier pharmaceutical companies obtained license rights to a product developed by a biotechnology company, thereby infusing much needed capital for furtherance of clinical research. In return, the pharmaceutical company obtained outright or major ity rights to marketing a...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Coming Into Focus
The pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according t...
By PharmaVoice Team • Oct. 23, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Beyond the Genome — Proteomics
Drug discovery in the postgenomic era will lead researchers to focus on the proteins and biological mechanisms that cause disease as a way to develop new types of treatments that are safer and more effective BY DENISE MYSHKO When the initial map of the human genome was first published in February...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
The Knowledge Revolution
In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...
By PharmaVoice Team • Aug. 24, 2009 -
PharmaVoice Team/PharmaVoice
The Creative Challenge
BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Cha...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
Vanlev: Coming Soon
In a second round for a drug that once was predicted to become a high flier, BristolMyers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, BristolMyers Squibb was s...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Consumer shifts demand changes in healthcare marketing In its latest report on market insights, Cheskin, a strategic market research and consulting company, defines three consumer trends that are driving the evolution of the healthcare and lifesci ences industry: consumer enlightenment and empowe...
By PharmaVoice Team • March 10, 2009 -
PharmaVoice Team/PharmaVoice
GLOBAL Development
BY DENISE MYSHKO Drug developers are looking to emerging markets and increasing their outsourcing efforts as ways to access expertise and reach. Pharmaceutical companies will continue to globalize their preclinical and clinical development activities to increase speed-to-market and expand their p...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
Buying Big GLOBAL
How M&A Impacts the Pharma Market As patent expirations and dwindling pipelines, along with an embattled economy, put a dent on pharma profits, acquisitions again become a necessity for large pharma companies seeking to maintain a healthy bottom line. With Pfizer’s purchase of Wyeth, among ot...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
Venture Capital: Funding Challenges
VENTURE CAPITAL: CAUTIOUS investment Venture capital firms are sitting on massive funds and are still doing deals, but their energies are focused on reinvesting in portfolio companies and safer latest age deals. As a result, it has never been harder for the early stage pure startup to get funded....
By PharmaVoice Team • Feb. 23, 2009 -
PharmaVoice Team/PharmaVoice
A Community Approach
As many pharmaceutical companies are finding, healthcare begins within the community, and a regional program, with health information that helps patients at a local level, might just win a company the hearts, minds, and ultimately buying power of those community members. For an industry confronte...
By PharmaVoice Team • Feb. 23, 2009 -
PharmaVoice Team/PharmaVoice
Delivering on the Promise
BY ELISABETH PENA Drug delivery promises FULLER PIPELINES, EXTENDED PRODUCT LIFE CYCLES, and IMPROVED PATIENT COMPLIANCE. AS THE PHARMACEUTICAL INDUSTRY FACES A FLOOD OF BLOCKBUSTER DRUG PATENT EXPIRATIONS, drug-delivery COMPANIES WILL HAVE THE CHANCE TO PROVE THEMSELVES. BY 2005 analysts predict...
By PharmaVoice Team • Feb. 23, 2009 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTHCARE-RELATED PRODUCTS, SERVICES, AND COMPANIES NOP World Health Forms a New Division to RESPOND TO PHARMACEUTICAL PUBLIC-RELATIONS CRISES Through a combination of in-depth therapeutic class analyses, events-driven Web research, and multi-stake holder image tracking and reputation assess...
By PharmaVoice Team • Feb. 22, 2009 -
PharmaVoice Team/PharmaVoice
Information Technology: Tracking the E-Volution
Pharmaceutical companies have long term plans, they have products that take a long time to develop, a long time to test to gain approval, and they have a shelf life. But technology moves so much faster than that. So the industry as a whole has had to adopt to the speed of technology. IAN CROSS BY...
By PharmaVoice Team • Feb. 21, 2009 -
PharmaVoice Team/PharmaVoice
The Practice of Public Relations
When effectively managed, public relations creates unique opportunities for marketers to provide con sumers and healthcare professionals with immediate and thorough drug and healthcare information. The healthcare publicrelations market in the United States grew 30% last year and is now valued at ...
By PharmaVoice Team • Feb. 21, 2009 -
PharmaVoice Team/PharmaVoice
No Pens or Mugs? No Problem.
The industry is discovering it won’t lose its ability to message effectively under the new PhRMA code. Under the new PhRMA code, the exhibit hall of the future will contain no tchotchkes. Sales reps will no longer stop by the physician’s office with donuts, pens, and sticky notes. The question is...
By PharmaVoice Team • Dec. 22, 2008 -
PharmaVoice Team/PharmaVoice
On The Calendar
January 15-16 Next Generation Clinical Research Associates Loews Philadelphia Hotel, Philadelphia Center for Business Intelligence, cbinet.com January 19-20 2nd Oncology Biomarkers Hilton Miami Downtown, Miami GTCbio, gtcbio.com January 19-20 Paediatric Clinical Trials Copthorne Tara Hotel, Londo...
By PharmaVoice Team • Dec. 22, 2008 -
PharmaVoice Team/PharmaVoice
Marketing
SALES & Marketing MARKETING Web 2.0 Marketing in 2009 AND BEYOND Pharma begins the move from informing to interacting and embracing the Web 2.0 revolution and emerging media options. BY Robin Robinson The industry has been using the Internet to inform and educate consumers for several years. ...
By PharmaVoice Team • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
Salesforces
SALES & Marketing Salesforces The Salesforce of the Future: MORE SERVICE, LESS SELL As companies — Sanofi-Aventis, Merck, Wyeth, Schering-Plough, Novartis — continue to make headlines for collectively laying off thousands of sales representatives, the industry looks for innovative ways to do ...
By PharmaVoice Team • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEB BASED APPLICATIONS, SITES, AND TECHNOLOGIES The latest interactive sales training guide from Total Learning Concepts, Introduction to Pharmaceutical Sales, uses the company’s serious gaming technology platform, Qube, to provide a comprehensive primer for under standing and ...
By PharmaVoice Team • Nov. 22, 2008 -
PharmaVoice Team/PharmaVoice
Hitting a Mobile Target
Hitting a Mobile Target By Carolyn Gretton “The pharmaceutical industry, in general, is relatively progressive when it comes to finding innovative solutions to its business problems," says James Carr, Pharm.D., VP of marketing, ARCA Biopharma. “The development may be partly held back by slow ele...
By PharmaVoice Team • Oct. 26, 2008 -
PharmaVoice Team/PharmaVoice
Marketing Inside the Lines
THE FORUM The industry has responded by drafting its own rules of conduct. In July, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a revised version of its 2002 Code on Interactions with Healthcare Professionals, a set of voluntary guidelines designed to ensure the foc...
By PharmaVoice Team • Sept. 16, 2008 -
PharmaVoice Team/PharmaVoice
When Smaller is Better
BY ROBIN ROBINSON As the industry turns its attention toward specialty products in the hopes of filling drying pipelines, smaller pharma and biotech companies may find themselves in the driver’s seat. Despite all of the hurdles facing the specialty industry — the FDA’s slow down in new drug appro...
By PharmaVoice Team • Sept. 1, 2008 -
PharmaVoice Team/PharmaVoice
A New Era of Drug Safety
BY DENISE MYSHKO NEW REGULATIONS IN THE UNITED STATES AND EUROPE HAVE TRIGGERED A NEED FOR BETTER TOOLS FOR THE COLLECTING, REPORTING,AND ANALYSIS OF PATIENT SAFETY DATA. As regulators around the globe demand more data on each drug’s profile, the need for technologies to support drug safety has b...
By PharmaVoice Team • Aug. 27, 2008 -
PharmaVoice Team/PharmaVoice
The Change Agents
Despite obstacles, these movers and shakers have shouldered the mantle of responsibility and are changing the industry for the better. Jason Appel Jay Bigelow Gregg Brandyberry Santino Costanzo Sean Cunliffe Kathleen Drennan Filipe Duarte Marc Ferrara Thomas Finn Colleen Foley Alberto Grignolo, P...
By PharmaVoice Team • July 24, 2008
Previous
